Furthermore, several studies have shown that combining GPX4 inhibition with EGFR blockade (e.g., cetuximab) or PI3K-AKT pathway inhibitors results in synergistic ferroptosis and tumor regression [82,83]. The gene discussed is GPX4; the disease is neoplasm.